Physiomics (PYC) Competitors GBX 0.47 +0.02 (+4.00%) As of 06/13/2025 09:54 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock PYC vs. EVG, MTFB, GENF, DEST, BSFA, ROQ, RENE, VAL, SALV, and TCFShould you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Evgen Pharma (EVG), Motif Bio (MTFB), Genflow Biosciences (GENF), Destiny Pharma (DEST), BSF Enterprise (BSFA), Roquefort Therapeutics (ROQ), ReNeuron Group (RENE), ValiRx (VAL), SalvaRx Group (SALV), and Theracryf (TCF). These companies are all part of the "biotechnology" industry. Physiomics vs. Its Competitors Evgen Pharma Motif Bio Genflow Biosciences Destiny Pharma BSF Enterprise Roquefort Therapeutics ReNeuron Group ValiRx SalvaRx Group Theracryf Physiomics (LON:PYC) and Evgen Pharma (LON:EVG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking. Is PYC or EVG more profitable? Evgen Pharma has a net margin of 0.00% compared to Physiomics' net margin of -106.80%. Evgen Pharma's return on equity of -60.57% beat Physiomics' return on equity.Company Net Margins Return on Equity Return on Assets Physiomics-106.80% -127.68% -76.38% Evgen Pharma N/A -60.57%-45.52% Which has more volatility and risk, PYC or EVG? Physiomics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Evgen Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Does the media favor PYC or EVG? In the previous week, Physiomics' average media sentiment score of 0.00 equaled Evgen Pharma'saverage media sentiment score. Company Overall Sentiment Physiomics Neutral Evgen Pharma Neutral Which has better earnings & valuation, PYC or EVG? Physiomics has higher revenue and earnings than Evgen Pharma. Physiomics is trading at a lower price-to-earnings ratio than Evgen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhysiomics£864.07K1.11-£922.82K-£0.45-1.05Evgen PharmaN/AN/A-£3.35M-£0.01N/A Do institutionals & insiders hold more shares of PYC or EVG? 27.8% of Evgen Pharma shares are held by institutional investors. 4.2% of Physiomics shares are held by insiders. Comparatively, 32.4% of Evgen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in PYC or EVG? Evgen Pharma received 113 more outperform votes than Physiomics when rated by MarketBeat users. Likewise, 74.23% of users gave Evgen Pharma an outperform vote while only 55.56% of users gave Physiomics an outperform vote. CompanyUnderperformOutperformPhysiomicsOutperform Votes8055.56% Underperform Votes6444.44% Evgen PharmaOutperform Votes19374.23% Underperform Votes6725.77% SummaryEvgen Pharma beats Physiomics on 8 of the 12 factors compared between the two stocks. Get Physiomics News Delivered to You Automatically Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter. Email Address PYC vs. The Competition Export to ExcelMetricPhysiomicsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£960K£124.82M£5.57B£2.91BDividend Yield6.20%3.74%5.28%4.90%P/E Ratio-1.053.2526.75124.60Price / Sales1.114,108.15408.11248,064.90Price / Cash4.2113.1938.2528.07Price / Book2.2435.866.964.64Net Income-£922.82K-£91.56M£3.23B£5.91B7 Day Performance1.74%0.34%-1.19%12.86%1 Month Performance12.50%6.24%8.50%25.97%1 Year Performance-66.57%180.82%33.53%77.95% Physiomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYCPhysiomicsN/AGBX 0.47+4.0%N/A-62.4%£960K£864.07K-1.0510Gap UpEVGEvgen PharmaN/AN/AN/AN/A£3.42MN/A-80.0010MTFBMotif BioN/AN/AN/AN/A£3.28MN/A-0.036GENFGenflow BiosciencesN/AGBX 0.88+3.5%N/A-74.1%£3M-£226.19K-1.665Gap DownDESTDestiny PharmaN/AN/AN/AN/A£2.87M£135.03K-50.0024Gap DownHigh Trading VolumeBSFABSF EnterpriseN/AGBX 2.13-10.3%N/A-59.9%£2.63M£80.25K-1.2912Gap UpROQRoquefort TherapeuticsN/AGBX 1.64-8.9%N/A-66.7%£2.09M£2.66K-1.359Gap DownRENEReNeuron GroupN/AN/AN/AN/A£1.93M£783K-37.502Gap DownVALValiRxN/AGBX 0.50+4.8%N/A-82.2%£1.89M£27.78K-0.345,450Earnings ReportGap UpSALVSalvaRx GroupN/AN/AN/AN/A£1.65M£64.50M0.032Gap UpTCFTheracryfN/AGBX 0.28+5.7%N/A-76.6%£1.34M£687.67K-0.2710Gap Up Related Companies and Tools Related Companies Evgen Pharma Competitors Motif Bio Competitors Genflow Biosciences Competitors Destiny Pharma Competitors BSF Enterprise Competitors Roquefort Therapeutics Competitors ReNeuron Group Competitors ValiRx Competitors SalvaRx Group Competitors Theracryf Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:PYC) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredOil Hits $74 - $100 Next?Oil Jumps 8.5% on Middle East Crisis Trump at Oil Fields Oil surged 8.5% to $74/barrel after Israel's Ir...The Oxford Club | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Physiomics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Physiomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.